FGF23 as a Marker of Acute Kidney Injury
Fibroblast Growth Factor-23 as a Marker of Acute Kidney Injury After Partial Nephrectomy
A partial nephrectomy (PN) preserves renal parenchyma with a proper oncology outcome. PN is performed during transitory ischemia to avoid massive bleeding during tumor resection. Nevertheless, the transitory ischemia might cause an acute kidney injury(AKI). AKI diagnose is based on the increase in plasma creatinine concentration and a decrease in urine output. However, both plasma creatinine concentration and diuresis are useful for the diagnose, but not in the detection of the risk patients. Therefore, there is considerable interest to find a biomarkers of kidney injury that allow clinicians to predict the development of AKI. Hence, we propose Fibroblastic Growth Factor-23 (FGF23) as a novel early biomarker to detect patients in risk to develop postoperative AKI after a PN.
We will conduct an observational and prospective study in three different groups of patients: PN gropup, patients who underwent PN with a transient and controlled renal ischemia injury using a renal artery clamping; Hemicolectomy (HC) group, patients as non-renal ischemia surgery controls, with similar demographic characteristics, but submitted to HC; and Nephrolithotomy (NL) group, patients who underwent NL, as a control of kidney surgery with physical injury.
In each patient, a time curve of plasmatic creatinine, blood urea nitrogen (BUN), and FGF23 were measure.
Our study aims to describe the role of FGF23 as an early biomarker of AKI after PN, where patients are exposed to a controlled ischemic injury.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiesteder
-
-
-
Santiago, Chile
- Rekruttering
- Hospital Clinic Universidad de Chile
-
Ta kontakt med:
- Nicolas J Valls, MD
- Telefonnummer: +56933741332
- E-post: nvallsj@hotmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- American Society of Anesthesiology physical status (ASA) I or II.
- Normal preoperative plasma creatinine level
- Baseline estimated glomerular filtration rate (eGFR) > 60 ml/min per 1.73 m2.
Exclusion Criteria:
- History of chronic kidney disease
- Anemia
- Alterations in the parathormone or vitamin D axis
- Pregnant women
- Subjects with concomitant use of nephrotoxic drugs.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Partial Nephrectomy (PN)
Patients that will undergo PN with a transient and controlled renal ischemia injury using a renal artery clamping.
|
Plasma levels of FGF-23 will be measured by ELISA
|
|
Hemicolectomy (HC)
Patients who will undergo HC, as non-renal ischemia surgery controls, with similar demographic characteristics, but submitted to HC.
|
Plasma levels of FGF-23 will be measured by ELISA
|
|
Nephrolithotomy (NL)
Patients who undergo NL as non-renal ischemia surgery controls but with kidney physical injury
|
Plasma levels of FGF-23 will be measured by ELISA
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Acute Kidney Injury
Tidsramme: 72 hours
|
Patients that develop postoperative acute kidney injury
|
72 hours
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- OAIC 868/17
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .